Clinical Trials Browser

Phase 2 × OTHER × mirdametinib × Clear all

NCT05983159 2026-02-19

TARGET-VM

Phase 2 Recruiting

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Phase 2 Recruiting

CNSDermatologic

Melanoma, Neurofibromatoses

NCT02096471 2019-01-10

MEK Inhibitor

Phase 2 Completed

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1